Author(s): Yuranga W, Bruno DM
BACKGROUND: In recent years, a number of randomized controlled trials (RCTs) have reported on lenalidomide as a treatment for multiple myeloma (MM). Herein, we report results of a meta-analysis of RCTs examining the efficacy and safety of lenalidomide for MM.
PATIENTS AND METHODS: Databases were searched using the terms "lenalidomide or revlimid AND multiple myeloma."RCTs evaluating initial or maintenance therapeutic outcomes were included. Main outcome measures were response rates, progression-free survival (PFS), overall survival, and adverse events.
RESULTS: Seven trials were included (N = 192-614 participants). Lenalidomide doses and treatment regimens differed between trials. Complete response (CR) and very good partial response (VGPR) risk ratios (RR) favored lenalidomide over placebo (CR = 2.54, 95% confidence interval [CI] = 1.29-5.02; VGPR = 2.82, 95% CI = 1.30-6.09). The PFS hazard ratio favored lenalidomide over placebo (0.37, 95% CI = 0.33-0.41). For adverse events, neutropenia, deep vein thrombosis (DVT), infection, and hematologic cancer RR favored placebo over lenalidomide (neutropenia: 4.74, 95% CI = 2.96-7.57; DVT: 2.52; 95% CI: 1.60-3.98; infection: 1.98; 95% CI: 1.50-2.62; hematologic cancer: 3.20; 95% CI: 1.28-7.98).
CONCLUSIONS: Lenalidomide is an effective treatment for MM; however, treatment-related adverse events must be considered and appropriate adjustments and/or prophylactic treatment should be initiated where possible.
Referred From: http://radiopaedia.org/articles/solitary-bone-plasmacytoma-1
Author(s): DimopoulosMA, Kiamouris C, Moulopoulos LA
Author(s): Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R
Author(s): Hu K, Yahalom J
Author(s): http://www
Author(s): Nofsinger YC, Mirza N, Rowan PT, Lanza D, Weinstein G
Author(s): Losa M, Terreni MR, Tresoldi M, Marcatti M, Campi A, et al.
Author(s): Jagadeesan J, Oudit D, Hardwicke J, Shariff Z, McCoubrey G, et al.
Author(s): Sinnott BP, Hatipoglu B, Sarne DH
Author(s): Elias HG, Scott J, Metheny L, Quereshy FA
Author(s): Pingali SR, Haddad RY, Saad A
Author(s): Campo E, Swedlow SH, Harris NL, Pileri S, Stein H, et al.
Author(s): Ozsahin M, Tsang RW, Poortmans P, Belkacemi Y, Bolla M,et al.
Author(s): Yang B, Yu RL, Chi XH, Lu XC
Author(s): Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, et al.